* Neogenomics Inc NEO.OQ NEO.O is expected to show a
rise in
quarterly revenue when it reports results on February 20 for
the period ending December 31 2023
* The Fort Myers Florida-based company is expected to
report a
10.0% increase in revenue to $152.535 million from $138.71
million a year ago, according to the mean estimate from 12
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Neogenomics Inc is for a
loss
of 2 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Neogenomics
Inc
is $19.00, above its last closing price of $14.90.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.06 -0.07 0.00 Beat 100
Jun. 30 2023 -0.11 -0.11 -0.05 Beat 56
Mar. 31 2023 -0.15 -0.15 -0.09 Beat 40.5
Dec. 31 2022 -0.15 -0.16 -0.06 Beat 63.6
Sep. -0.20 -0.21 -0.14 Beat 32
30 2022
Jun. 30 2022 -0.20 -0.23 -0.16 Beat 29
Mar. 31 2022 -0.24 -0.24 -0.20 Beat 15
Dec. 31 2021 -0.14 -0.15 -0.14 Beat 3.8
This summary was machine generated February 16 at 23:07 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)